Faeth Therapeutics, Inc. (FTH)
28.00
-1.05
(-3.61%)
USD |
NASDAQ |
Sep 25, 16:00
27.75
-0.25
(-0.89%)
Pre-Market: 19:59
Faeth Therapeutics Enterprise Value : 544.24M for Sept. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 544.24M |
| September 24, 2026 | 571.37M |
| September 23, 2026 | 635.95M |
| September 22, 2026 | 683.74M |
| September 21, 2026 | 680.90M |
| September 18, 2026 | 712.16M |
| September 17, 2026 | 728.43M |
| September 16, 2026 | 705.44M |
| September 15, 2026 | 734.63M |
| September 14, 2026 | 830.73M |
| September 11, 2026 | 788.11M |
| September 10, 2026 | 828.40M |
| September 09, 2026 | 754.01M |
| September 08, 2026 | 833.57M |
| September 04, 2026 | 855.53M |
| September 03, 2026 | 828.40M |
| September 02, 2026 | 831.50M |
| September 01, 2026 | 712.41M |
| August 31, 2026 | 667.47M |
| August 28, 2026 | 695.11M |
| August 27, 2026 | 692.52M |
| August 26, 2026 | 672.63M |
| August 25, 2026 | 712.67M |
| August 24, 2026 | 717.58M |
| August 21, 2026 | 647.57M |
| Date | Value |
|---|---|
| August 20, 2026 | 650.16M |
| August 19, 2026 | 676.25M |
| August 18, 2026 | 673.41M |
| August 17, 2026 | 667.47M |
| August 14, 2026 | 656.36M |
| August 13, 2026 | 558.45M |
| August 12, 2026 | 579.89M |
| August 11, 2026 | 595.91M |
| August 10, 2026 | 558.97M |
| August 07, 2026 | 450.98M |
| August 06, 2026 | 453.31M |
| August 05, 2026 | 456.15M |
| August 04, 2026 | 479.66M |
| August 03, 2026 | 527.19M |
| July 31, 2026 | 524.61M |
| July 30, 2026 | 565.43M |
| July 29, 2026 | 568.27M |
| July 28, 2026 | 573.43M |
| July 27, 2026 | 576.27M |
| July 24, 2026 | 551.73M |
| July 23, 2026 | 538.04M |
| July 22, 2026 | 561.29M |
| July 21, 2026 | 553.80M |
| July 20, 2026 | 549.15M |
| July 17, 2026 | 489.22M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Opus Genetics, Inc. | 340.80M |
| Perspective Therapeutics, Inc. | 54.58M |
| Praxis Precision Medicines, Inc. | 7.081B |
| Nuvectis Pharma, Inc. | 517.61M |
| Jade Biosciences, Inc. | 455.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.01M |
| Total Expenses (Quarterly) | 16.01M |
| EPS Diluted (Quarterly) | -2.836 |
| Earnings Yield | -505.9% |
| Normalized Earnings Yield | -232.43 |